China Medical Technologies’ wholly-owned subsidiary, Beijing GP Medical Technologies Co., Ltd., has signed a partnership agreement with Gaoxin Da An Healthcare Investment Ltd. to co-market and promote molecular diagnostic technologies for clinical diagnostic applications in China.
Both the parties will also work jointly to develop new molecular diagnostic products to cater for Da An Health's hospital customers.
"We are excited to become a strategic partner of GP Medical," commented Mr. Yong Zhang, Chief Executive Officer of Da An Health, in a press release.
"Molecular diagnostic market in China has huge potential to grow. Our ability to serve and reach a large number of healthcare institutions which brings each individual hospital demand to a large test volume, complement with GP Medical's outstanding molecular diagnostic product portfolio. Working together, we can better serve a larger number of healthcare institutions in China."
GP Medical and Da An Health, as per the agreement, will promote and offer the use of GP Medical's molecular diagnostic products to the customer base of Da An Health. Owing to this,
GP Medical's existing direct sales network covering large hospitals will be expanded to the customer network of Da An Health covering some of the large hospitals that GP Medical did not cover.
Additionally, both the parties will also develop innovative molecular diagnostic product packages or solutions to offer to Da An Health hospital customers. The validation of the new product packages or solutions will take place at the independent laboratories of Da An Health.
Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company, said: "We believe this collaboration will promote our brand name as well as product awareness to a new customer base through Da An Health. We can also get ideas of the hospital demand from this collaboration to prioritize our product development to support our sustainable growth in the future."
In healthcare related news, Medidata Solutions has entered into a definitive agreement to acquire Clinical Force, a pioneer in providing SaaS-based clinical trial management systems.
Deepika Mala is a contributing editor for HealthTechZone. To read more of her articles, please visit her columnist page.
